Skip to content
value.today
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc.

HRTX
$57 Mmarket cap on Oct 28, 2026-78.0% since Jan 2024
Compare
World rank
#20,806
Revenue
$155 M
For year ending December-2025
Net income
$-20 M
-13.0% margin
SEC filing
Employees
302
As on 2021
value.today research

Heron Therapeutics, Inc. in brief

Heron Therapeutics, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $57 M on 28 October 2026, which makes it the 20,806th largest listed company in the world and the 3,801st largest in the USA on this site. In the year to December 2025 it had sales of $155 M and a net loss of $20 M. It employs about 302 people and Craig A. Collard is its chief executive. Its largest product and service lines by sales in 2025 were CINVANTI (62%), ZYNRELEF (25%) and APONVIE (7%). Its shares trade under the symbol HRTX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Heron Therapeutics, Inc.

Heron Therapeutics is a Developing and Commercializing Pharmaceutical Products company. The headquarters is in USA.

Heron Therapeutics, Inc. timeline

4 events, 1994–2025
  1. 1994
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2001
  4. ✎
    Renamed Ap Pharma Inc /De/
    Formerly Advanced Polymer Systems Inc /De/.
  5. 2014
  6. ✎
    Renamed Heron Therapeutics, Inc. /De/
    Formerly Ap Pharma Inc /De/.
  7. 2025
  8. 💰
    Record revenue of $155 million
    FY2025, the highest of the 8 years on record.

Events of Heron Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$559 M$1.1 B$1.7 B$2.2 B2020202120222023202420252026

World rank over time

▼ down 15,834 places since 2020
2020-01-01: #5016#5,01620202021-01-01: #5591#5,59120212022-01-07: #10044#10,04420222022-12-25: #15577#15,57720222023-07-30: #18405#18,40520232024-01-05: #16546#16,54620242026-03-08: #9130#9,13020262026-08-01: #18749#18,74920262026-10-13: #19667#19,66720262026-10-28: #20850#20,8502026

Rank in USA: #1,518 (Jan 2020) · #1,677 (Jan 2021) · #2,655 (Jan 2022) · #3,185 (Dec 2022) · #3,664 (Jul 2023) · #3,054 (Jan 2024) · #1,740 (Mar 2026) · #3,644 (Aug 2026) · #3,615 (Oct 2026) · #3,805 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.4×
Price / book
4.0×
Free cash flow yield
-48.9%
Net margin (TTM)
-14.6%
Operating margin
-1.6%
Return on equity
-150.5%
Liabilities / assets
94.4%
Revenue growth
+7.4%
R&D / revenue
8.0%
Revenue per employee
$513 K
Profit per employee
$-67 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $77M, net income $-179M$77MFY18Fiscal year ending Dec 2019: revenue $146M, net income $-205M$146MFY19Fiscal year ending Dec 2020: revenue $89M, net income $-227M$89MFY20Fiscal year ending Dec 2021: revenue $86M, net income $-221M$86MFY21Fiscal year ending Dec 2022: revenue $108M, net income $-182M$108MFY22Fiscal year ending Dec 2023: revenue $127M, net income $-111M$127MFY23Fiscal year ending Dec 2024: revenue $144M, net income $-14M$144MFY24Fiscal year ending Dec 2025: revenue $155M, net income $-20M$155MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$155M+7.4%$-3M$-20M-13.0%
Dec 2024$144M+13.6%$-12M$-14M-9.4%
Dec 2023$127M+18.0%$-111M$-111M-87.0%
Dec 2022$108M+24.7%$-175M$-182M-169.1%
Dec 2021$86M-2.6%$-218M$-221M-255.6%
Dec 2020$89M-39.3%$-228M$-227M-256.4%
Dec 2019$146M+88.4%$-211M$-205M-140.3%
Dec 2018$77M—$-184M$-179M-230.9%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-28M$0M$-28M$-0.12—
Dec 2024$-23M$2M$-24M$-0.09—
Dec 2023$-59M$2M$-60M$-0.80—
Dec 2022$-147M$2M$-149M$-1.67—
Dec 2021$-203M$3M$-206M$-2.24—
Dec 2020$-185M$7M$-192M$-2.50—
Dec 2019$-125M$7M$-132M$-2.50—
Dec 2018$-192M$9M$-201M$-2.44—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$148M
Net income, trailing 12 months
$-22M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $41M, net income $4M$41MDec ’24Three months to Mar 2025: revenue $39M, net income $3M$39MMar ’25Three months to Jun 2025: revenue $37M, net income $-2M$37MJun ’25Three months to Sep 2025: revenue $38M, net income $-18M$38MSep ’25Three months to Dec 2025 (from the annual report): revenue $41M, net income $-3M$41MDec ’25Three months to Mar 2026: revenue $35M, net income $-8M$35MMar ’26Three months to Jun 2026: revenue $38M, net income $-5M$38MJun ’26Three months to Sep 2026: revenue $35M, net income $-5M$35MSep ’26

Latest quarter to Sep 2026: revenue $35M (-7.7% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Heron Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$155 M
Operating income
$-3 M
Net income
$-20 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$256 M
Total liabilities
$242 M
Total equity
$14 M

As of December-2025

Top 100 institutional investors in Heron Therapeutics, Inc.#

As of Sep 30, 2026
159 institutions held 123.7 M shares (about 65.0% of the shares outstanding) on Sep 30, 2026. The ten largest hold 50.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Heron Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Rubric Capital Management LP30,046,8280 (0.00%)15.79%$9 MNov 16, 2026
2Clearline Capital LP11,026,633-357,328 (-3.14%)5.80%$3 MNov 16, 2026
3BlackRock, Inc.9,826,332-724,418 (-6.87%)5.16%$3 MNov 13, 2026
4Tang Capital Management LLC8,971,427+2,721,427 (+43.54%)4.71%$3 MNov 16, 2026
5Velan Capital Investment Management LP8,753,2900 (0.00%)4.60%$3 MNov 16, 2026
6Vanguard Capital Management LLC7,820,161+37,420 (+0.48%)4.11%$2 MNov 13, 2026
7Tejara Capital Ltd6,492,878-17,917 (-0.28%)3.41%$2 MNov 9, 2026
8Gsa Capital Partners LLP5,473,797+4,430,905 (+424.87%)2.88%$2 MNov 16, 2026
9Geode Capital Management, LLC4,106,017-164,963 (-3.86%)2.16%$1 MNov 6, 2026
10State Street Corp3,203,401-25,156 (-0.78%)1.68%$1 MNov 12, 2026
11UBS Group AG2,105,269-891,804 (-29.76%)1.11%$1 MNov 10, 2026
12AQR Capital Management LLC1,987,205+433,348 (+27.89%)1.04%$1 MNov 16, 2026
13Renaissance Technologies LLC1,569,100+62,200 (+4.13%)0.82%$0 MNov 12, 2026
14Millennium Management LLC1,459,918-2,610,183 (-64.13%)0.77%$0 MNov 16, 2026
15Caption Management, LLC1,383,994+383,994 (+38.40%)0.73%$0 MNov 16, 2026
16Vanguard Portfolio Management LLC1,370,188-210,322 (-13.31%)0.72%$0 MNov 13, 2026
17Panagora Asset Management Inc1,323,436+41,640 (+3.25%)0.70%$0 MNov 12, 2026
18Goldman Sachs Group Inc1,258,587-71,167 (-5.35%)0.66%$0 MNov 16, 2026
19Vanguard Fiduciary Trust Co1,225,732-139,387 (-10.21%)0.64%$0 MNov 13, 2026
20Northern Trust Corp1,206,459-17,021 (-1.39%)0.63%$0 MNov 16, 2026
21CM Management, LLC1,000,0000 (0.00%)0.53%$0 MNov 12, 2026
22Invesco Ltd.662,160+255,492 (+62.83%)0.35%$0 MNov 12, 2026
23Squarepoint Ops LLC600,287+279,110 (+86.90%)0.32%$0 MNov 9, 2026
24Congress Park Capital LLC551,697-1,464,750 (-72.64%)0.29%$0 MOct 13, 2026
25Citadel Advisors LLC477,208New0.25%$0 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Heron Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Nexpoint Asset Management, L.P.475,7500 (0.00%)0.25%$0 MNov 16, 2026
27Xcelsior Advisor Partners LLC466,777+61,000 (+15.03%)0.25%$0 MNov 13, 2026
28Diadema Partners LP458,7230 (0.00%)0.24%$0 MNov 16, 2026
29Acadian Asset Management LLC394,134+241,123 (+157.59%)0.21%$0 MNov 9, 2026
30Bank of New York Mellon Corp378,609-17,229 (-4.35%)0.20%$0 MNov 5, 2026
31Marshall Wace, LLP357,515-1,996,678 (-84.81%)0.19%$0 MNov 13, 2026
32Two Sigma Investments, LP346,014+79,700 (+29.93%)0.18%$0 MNov 16, 2026
33Apeiron RIA LLC319,123-51,456 (-13.89%)0.17%$0 MOct 8, 2026
34Barclays PLC310,479+219,457 (+241.10%)0.16%$0 MNov 6, 2026
35Charles Schwab Investment Management Inc307,680-909,783 (-74.73%)0.16%$0 MNov 16, 2026
36Nuveen, LLC304,443+82,656 (+37.27%)0.16%$0 MNov 10, 2026
37Alliancebernstein L.P.299,9100 (0.00%)0.16%$0 MNov 16, 2026
38StoneX Group Inc.237,550New0.12%$0 MNov 3, 2026
39Los Angeles Capital Management LLC210,883+90,590 (+75.31%)0.11%$0 MNov 12, 2026
40Bank Of America Corp /de/180,519+72,150 (+66.58%)0.09%$0 MNov 16, 2026
41Rhumbline Advisers180,444-15,093 (-7.72%)0.09%$0 MNov 10, 2026
42Quinn Opportunity Partners LLC175,3440 (0.00%)0.09%$0 MNov 10, 2026
43Qube Research & Technologies Ltd172,739-848,353 (-83.08%)0.09%$0 MNov 13, 2026
44Integrated Wealth Concepts LLC169,212+9,215 (+5.76%)0.09%$0 MNov 17, 2026
45Raymond James Financial Inc168,177+10,000 (+6.32%)0.09%$0 MNov 12, 2026
46BNP Paribas Financial Markets158,212+135,705 (+602.95%)0.08%$0 MNov 12, 2026
47Morgan Stanley155,797+44,099 (+39.48%)0.08%$0 MNov 13, 2026
48JW Asset Management, LLC140,863-3,610,210 (-96.24%)0.07%$0 MNov 6, 2026
49Persistent Asset Partners Ltd117,0900 (0.00%)0.06%$0 MNov 13, 2026
50Price T Rowe Associates Inc /MD/111,5040 (0.00%)0.06%$0 MNov 16, 2026
51Glenmede Trust Co NA105,326New0.06%$0 MNov 16, 2026
52HSBC Holdings PLC100,000+66,619 (+199.57%)0.05%$0 MNov 16, 2026
53Biltmore Family Office, LLC100,0000 (0.00%)0.05%$0 MNov 3, 2026
54Tudor Investment Corp Et Al94,864New0.05%$0 MNov 16, 2026
55SEI Investments Co91,036+78,351 (+617.67%)0.05%$0 MNov 10, 2026
56Richmond Brothers, Inc.87,344-1,704,975 (-95.13%)0.05%$0 MNov 13, 2026
57Searle & Co.86,2500 (0.00%)0.05%$0 MNov 4, 2026
58Ieq Capital, LLC85,899-10,713 (-11.09%)0.05%$0 MNov 10, 2026
59Deutsche Bank AG\84,183-12,117 (-12.58%)0.04%$0 MNov 6, 2026
60Vanguard Global Advisers, LLC84,053+297 (+0.35%)0.04%$0 MNov 13, 2026
61D. E. Shaw & Co., Inc.81,666-38,769 (-32.19%)0.04%$0 MNov 16, 2026
62Susquehanna International Group, LLP81,444-55,623 (-40.58%)0.04%$0 MNov 16, 2026
63Russell Investments Group, Ltd.81,2460 (0.00%)0.04%$0 MNov 6, 2026
64MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.77,457+3,872 (+5.26%)0.04%$0 MNov 16, 2026
65Mercer Global Advisors Inc /adv73,857+5,566 (+8.15%)0.04%$0 MNov 16, 2026
66Jpmorgan Chase & Co71,925-3,740 (-4.94%)0.04%$0 MNov 12, 2026
67Cerity Partners LLC65,795+5,454 (+9.04%)0.03%$0 MNov 13, 2026
68R Squared Ltd62,671+15,963 (+34.18%)0.03%$0 MNov 6, 2026
69LPL Financial LLC62,328+1,216 (+1.99%)0.03%$0 MNov 6, 2026
70Commonwealth Equity Services, LLC59,1760 (0.00%)0.03%$0 MNov 2, 2026
71Creative Planning57,128+21,266 (+59.30%)0.03%$0 MNov 2, 2026
72Redwood Family Wealth LLC55,972-49,500 (-46.93%)0.03%$0 MOct 20, 2026
73Captrust Financial Advisors52,950+1,403 (+2.72%)0.03%$0 MNov 12, 2026
74Wells Fargo & Company/mn51,379-101,544 (-66.40%)0.03%$0 MNov 16, 2026
75Vanguard Personalized Indexing Management, LLC47,209+19,933 (+73.08%)0.02%$0 MNov 16, 2026
76DLK Investment Management, LLC44,710+26,820 (+149.92%)0.02%$0 MOct 9, 2026
77Mariner, LLC41,746-14,226 (-25.42%)0.02%$0 MNov 12, 2026
78Public Employees Retirement System Of Ohio41,640New0.02%$0 MNov 16, 2026
79HORAN Wealth, LLC41,5900 (0.00%)0.02%$0 MNov 12, 2026
80Centiva Capital, LP40,083-5,424 (-11.92%)0.02%$0 MNov 13, 2026
81New Harbor Financial Group, LLC39,120New0.02%$0 MOct 22, 2026
82Police & Firemen's Retirement System of New Jersey38,3520 (0.00%)0.02%$0 MNov 9, 2026
83Prospera Financial Services Inc36,085-4,480 (-11.04%)0.02%$0 MNov 4, 2026
84King Wealth Management Group34,799+2,000 (+6.10%)0.02%$0 MNov 9, 2026
85DDFG, Inc32,9030 (0.00%)0.02%$0 MOct 15, 2026
86Tower Research Capital LLC (TRC)32,609-2,958 (-8.32%)0.02%$0 MNov 16, 2026
87Group One Trading LLC32,110-5,837 (-15.38%)0.02%$0 MNov 10, 2026
88Concurrent Investment Advisors, LLC31,9230 (0.00%)0.02%$0 MOct 16, 2026
89Pallas Capital Advisors LLC31,133+5,434 (+21.14%)0.02%$0 MNov 12, 2026
90Horizon Investments, LLC30,000New0.02%$0 MNov 13, 2026
91Wealth Enhancement Advisory Services, LLC29,067-3,330 (-10.28%)0.02%$0 MOct 13, 2026
92CoreCap Advisors, LLC28,4090 (0.00%)0.01%$0 MOct 8, 2026
93Diversified Trust Co26,4920 (0.00%)0.01%$0 MNov 6, 2026
94Royal Bank Of Canada26,154+20,694 (+379.01%)0.01%$0 MNov 16, 2026
95ACT Advisors, LLC.25,581New0.01%$0 MOct 15, 2026
96J.W. Cole Advisors, Inc.25,000+10,000 (+66.67%)0.01%$0 MNov 5, 2026
97Parkway Wealth Management Group, LLC25,0000 (0.00%)0.01%$0 MOct 20, 2026
98Prudential Financial Inc23,4950 (0.00%)0.01%$0 MNov 16, 2026
99&partners22,927-705 (-2.98%)0.01%$0 MNov 16, 2026
100HighTower Advisors, LLC22,263-2,354 (-9.56%)0.01%$0 MNov 10, 2026

All 159 institutional investors, with who bought and sold →

Mutual funds holding Heron Therapeutics, Inc.#

84 funds hold shares worth $12 M (about 17.7% of the company). Since their previous reports 26 added shares and 34 sold, selling $1 M net.
Mutual funds holding Heron Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.5.47 M$2 M4.2%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors3.68 M$2 M2.9%<0.01%−4.8%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.2.06 M$1 M1.6%<0.01%+1.7%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.63 M$1 M1.3%<0.01%+7.9%Jul 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.869,904$1 M0.67%<0.01%−1.6%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.783,992$1 M0.61%<0.01%+3.3%May 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors1.36 M$1 M1.1%<0.01%+786%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC666,160$1 M0.52%<0.01%−22%May 31, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.415,508$0 M0.32%<0.01%−0.8%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC318,641$0 M0.25%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC273,188$0 M0.21%<0.01%+3.9%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors537,335$0 M0.42%0.02%+39%Jun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors510,428$0 M0.40%<0.01%−56%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.413,595$0 M0.32%<0.01%+22%Jul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC265,032$0 M0.21%<0.01%no changeJun 30, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors241,129$0 M0.19%<0.01%+2.4%Jun 30, 2026
🇺🇸 Highland Global Allocation FundHighland Global Allocation Fund232,800$0 M0.18%0.03%no changeJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC198,783$0 M0.15%<0.01%no changeJul 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC198,800$0 M0.15%<0.01%−9.7%Jul 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.103,673$0 M0.08%<0.01%+4.8%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC88,334$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC175,959$0 M0.14%<0.01%no changeJun 30, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.83,361$0 M0.06%<0.01%+1.2%May 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.162,509$0 M0.13%<0.01%+94%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC157,240$0 M0.12%<0.01%+48%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC137,543$0 M0.11%<0.01%+901%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.129,323$0 M0.10%<0.01%−33%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC128,160$0 M0.10%<0.01%+65%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company62,537$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation118,392$0 M0.09%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.115,110$0 M0.09%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC88,576$0 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION45,455$0 M0.04%0.02%−16%May 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC76,332$0 M0.06%<0.01%+13%Jul 31, 2026
🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION40,788$0 M0.03%0.02%−16%May 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC66,714$0 M0.05%<0.01%+8.6%Jul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC64,721$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC49,610$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.48,817$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.48,604$0 M0.04%<0.01%−14%Jun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS37,137$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION20,900$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC40,509$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC33,418$0 M0.03%<0.01%+19%Jul 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.18,407$0 M0.01%<0.01%+2.7%May 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC36,443$0 M0.03%<0.01%+29%Jun 30, 2026
🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust34,050$0 M0.03%<0.01%−16%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS28,777$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC28,685$0 M0.02%<0.01%−83%Jun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors28,254$0 M0.02%<0.01%−0.8%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.12,513$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC12,300$0 M<0.01%<0.01%−51%May 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC20,897$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.23,391$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.20,226$0 M0.02%<0.01%−4.7%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC17,391$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC20,025$0 M0.02%<0.01%+1023%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.19,769$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC19,468$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors17,474$0 M0.01%<0.01%−22%Jun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management15,618$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC7,231$0 M<0.01%<0.01%+8.6%May 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC13,394$0 M0.01%<0.01%+13%Jun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC11,114$0 M<0.01%<0.01%+1134%Jul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC12,671$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC11,993$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC5,714$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC5,655$0 M<0.01%<0.01%−41%May 31, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC10,661$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC10,051$0 M<0.01%<0.01%−94%Jun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC4,679$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC4,190$0 M<0.01%<0.01%−5.2%May 31, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC6,399$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC5,088$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC5,641$0 M<0.01%<0.01%−56%Jun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC4,710$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC4,372$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC3,854$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.3,827$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC3,307$0 M<0.01%<0.01%−1.4%Jun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC960$0 M<0.01%<0.01%−80%Jul 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC1,020$0 M<0.01%<0.01%+8.9%Jul 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC800$0 M<0.01%<0.01%−64%Jun 30, 2026
🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC268$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 84 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Heron Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
36
since
$6.2 M$0Nov 2023: bought $288 K (4 trades), sold $0 (0 trades)Nov 23Aug 2025: bought $6.2 M (2 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Heron Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Mark Earl HensleyChief Operating OfficerOption exercise+31,250——210,572Form 4
filed Mark Earl HensleyChief Operating OfficerShares withheld for tax-8,889$0.290$3 K201,683Form 4
filed Ira DuarteEVP, Chief Financial OfficerOption exercise+11,695——306,051Form 4
filed Craig A. CollardChief Executive Officer, DirectorOption exercise+34,788——939,557Form 4
filed William P. ForbesEVP, Chief Development OfficerOption exercise+11,695——264,061Form 4
filed William P. ForbesEVP, Chief Development OfficerShares withheld for tax-3,327$0.280$932260,734Form 4
filed Craig A. CollardChief Executive Officer, DirectorShares withheld for tax-8,471$0.280$2 K931,086Form 4
filed Ira DuarteEVP, Chief Financial OfficerShares withheld for tax-3,327$0.280$932302,724Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Heron Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
34.0 M
18.1% of shares · 19.54 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 224,110 shares at $0.30
  • : 34,726 shares at $0.34
  • : 12,912 shares at $0.35
  • : 712 shares at $0.38
  • : 63,562 shares at $0.36

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Heron Therapeutics, Inc. scorecard#

Passes 8 of the 19 checks that could be worked out: strongest in growth (4 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median4.0×Price to book 4.0× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median0.4×Price to sales 0.4× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-48.9%Free cash flow is -48.9% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 6
    • ✓Revenue grew in the newest year7.4%Revenue up 7.4% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years12.9%12.9% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median12.9%12.9% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-0.12 vs -0.09Diluted EPS -0.12 in fiscal 2025 against -0.09 the year before (report's currency).
    • ✓Net income higher than five years earlier-$20 M-$20 M in fiscal 2025 against -$227 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability2 of 4
    • ✗Profitable in the newest year-$20 MNet income -$20 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median-1.6%-1.6% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-1.6%-1.6% in fiscal 2025 against -162.2% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.5×Current ratio 2.48 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-9.23Z-score -9.23 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year9.3%Diluted shares up 9.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Heron Therapeutics, Inc.'s statements, beside the median of Biotechnology.

Heron Therapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-1.6%-60.5%
Net margin-13.0%-68.9%
Revenue growth, 3 years a year12.9%12.9%
Revenue growth7.4%15.8%
Free cash flow margin-18.0%-61.5%

2of 8on the Piotroski tests of financial strength

  • Net loss of $20 million, the 17th loss-making year in a row.
  • Free cash flow was negative: -$28 million.
  • The share count rose 9.3% in the year.
  • Revenue has grown 4 years in a row.

Heron Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Heron Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue155144127108868914677311.3
Cost of revenue41396555463662284.60.0
Gross profit1141066253——————
Research and development121739r83r131175167140139103
Selling and marketing49476883876490655748
General and administrative555366r62r404238292621
Operating expenses———————261225172
Total costs and expenses116117173227r304317357261225—
Operating income−2.5−12−111−175−218−228−211−184−195−171
Interest and finance income1.93.63.41.60.43.67.36.01.00.4
Interest expense and finance costs9.66.03.92.52.41.91.52.73.92.7
Other non-operating income (expense)−18−2.10.1−7.4−2.90.95.95.1−2.9−2.2
Income tax0000000000
Net income including minority interests−20−14−111———————
Net income attributable to shareholders−20−14−111−182−221−227−205−179−197−173
Earnings per share, basic-0.12-0.09-0.80-1.67-2.24-2.50-2.50-2.44-3.65-4.56
Earnings per share, diluted-0.12-0.09-0.80-1.67-2.24-2.50-2.50-2.44-3.65-4.56
Shares, weighted average (basic)167152138109r0.1—————
Shares, weighted average (diluted)167152138109r0.1r9182735438
Balance sheet
Cash and cash equivalents2926291591105723214513
Short-term investments1833526967103319301——
Receivables9079605235424065422.0
Inventory9353425548422539105.3
Other current assets9.1186.114132223113.73.7
Current assets23820918920525431447944722862
Property, plant and equipment12152022242320156.05.1
Right-of-use (leased) assets02.85.47.69.81614———
Total assets25623322325130635451346223467
Accounts payable9.0123.23.23.80.52.817196.8
Current liabilities9691808271103979210339
Lease liabilities (non-current)0—2.85.58.01512———
Total liabilities2422672562372281171099210389
Retained earnings−1,940−1,920−1,906−1,795−1,613−1,393−1,165−961−783−586
Shareholders' equity14−34−341478236404370131−21
Total liabilities and equity25623322325130635451346223467
Shares outstanding188152150119r10291907865r0.0r
Cash-flow statement
Depreciation and amortization2.32.52.92.93.02.82.01.51.51.1
Share-based compensation10133343475051333126
Cash from operating activities−28−23−59−147−203−185−125−192−170−134
Capital expenditure−0.3−1.7−1.5−1.8−3.0−6.8−7.2−9.2−2.6−3.1
Cash from investing activities161918−3.333209−22−2797.715
Debt repaid———————−25−25—
Shares issued18—3075——162363306—
Cash from financing activities140.954751569.118635829457
Change in cash2.8−2.913−75−153340−113131−62
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Heron Therapeutics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • CINVANTI$97 M62%
  • ZYNRELEF$38 M25%
  • APONVIE$12 M7.5%
  • SUSTOL$9 M5.5%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Heron Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$3.5 M
Craig A. Collard
Other top executives, average
$2.5 M
the CEO earned 1.4× this
$100 invested is now
$6
peer group: $120
Heron Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Craig A. Collard$3.5 M$2.0 M$2.5 M$6 (peers $120)
2024Craig A. Collard$3.4 M$3.5 M$1.5 M$7 (peers $91)
2023Craig A. Collard$10.8 M$10.9 M$1.6 M$8 (peers $92)
2022Barry Quart$1.1 M−$2.8 M$1.4 M$12 (peers $89)
2021Barry Quart$5.4 M−$1.0 M$1.6 M$43 (peers $99)

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Heron Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 3 · Material agreement 9 · New debt 1 · Unregistered share sale 1 · Shareholder rights changed 3 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 8

Heron Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementShareholder rights changed8-K
Results announced8-K
Material agreement8-K
Material agreementShareholder rights changed8-K
Results announced8-K
Delisting notice8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Material agreement8-K
Material agreementShareholder rights changedBylaws or fiscal year changed8-K
Material agreement8-K
Material agreementBylaws or fiscal year changed8-K
Material agreementNew debtUnregistered share saleResults announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Heron Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2023$30 MPrivate placement after listing$10 to $50 million7equity, optionsSEC
Jul 2012$54 MPrivate placement after listing$50 to $250 million21equitySEC
Jul 2011$24 MA long-registered or listed company$10 to $50 million22equity, optionsSEC
Oct 2009$8 MA long-registered or listed company$2 to $10 million7equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Heron Therapeutics, Inc.#

$200 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues and medicare/medicaid.

Lobbying, 2025
$200 K
#1,002 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$150 K
  • Health Issues4 reports
  • Medicare/Medicaid4 reports

Lobbying firms hired in 2025

Farragut Partners LLP $200 K

Heron Therapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$150 K—3
2025$200 K—4
2024$200 K—4
2023$200 K—4
2022$200 K—4
2021$200 K—4
2020$200 K—4
2019$250 K—5
2018$340 K—7

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Heron Therapeutics, Inc.” and “Farragut Partners LLP on behalf of Heron Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Heron Therapeutics, Inc.#

2 labor condition applications certified in fiscal 2021 for 2 positions, at a median wage of $170 K a year.

Certified, FY2021
2
#1,614 among companies on value.today
Worker positions
2
Median wage offered
$170 K
a year, full-time
Applications filed
2
Heron Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2021
Job titlePositionsMedian wage offered
Associate Director, Pharmaceutical SciencesChemical Engineers1$140 K
Senior Director Business Analysis & InsightsManagement Analysts1$200 K

Where: Jersey City, NJ 1 · San Diego, CA 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Heron Therapeutics, Inc.

FDA drug approvals: Heron Therapeutics, Inc.#

4 approved applications held, 1 of them new molecular entities; 0 approvals and 1 new uses in 2024.

Approvals held
4
New molecular entities
1
New uses approved
4
efficacy supplements
Generics
0
4 new drugs, 0 biologics
Heron Therapeutics, Inc.: latest FDA approvals
ApprovedDrugKind
2024-01-23Zynrelef Kitnew useBupivacaine, Meloxicam · NDA211988 (SUPPL-13)New drug (NDA)
2022-09-16Aponvienew moleculeAprepitant · NDA216457New drug (NDA)
2021-12-08Zynrelef Kitnew useBupivacaine, Meloxicam · NDA211988 (SUPPL-5)New drug (NDA)
2021-05-12Zynrelef KitBupivacaine, Meloxicam · NDA211988New drug (NDA)
2019-10-21Cinvantinew useAprepitant · NDA209296 (SUPPL-4)New drug (NDA)
2019-02-26Cinvantinew useAprepitant · NDA209296 (SUPPL-3)New drug (NDA)
2017-11-09CinvantiAprepitant · NDA209296New drug (NDA)
2016-08-09SustolGranisetron · NDA022445New drug (NDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (HERON THERAPS INC), so they follow acquisitions

Product recalls by Heron Therapeutics, Inc.#

1 recalls since 2015, 1,790 units in the notices that give a number. Drugs (FDA): 1.

Heron Therapeutics, Inc.: product recalls
DateWhat and whyUnitsNotice
Zynrelef (bupivacaine and meloxicam), 400 mg bupivacaine and 12 mg meloxicam single dose application, packaged in a kit, Rx only, Manufactured for Heron Therapeutics, Inc., San Diego, CA, NDC 47426-301-02Defective Delivery System: An incorrect 10 mL (12 mL) Luer (slip) syringe packaged in one lot of Zynrelef 400 mg/12 mg kitDrugsClass III1,790D-1335-2022

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

Layoffs at Heron Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
77
2008–2022
Latest
77 people
2022-06-29
Heron Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2022·····77······77
2008············—
Heron Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
effective 77 peopleLayoffWARN noticeSan Diego, CaliforniaNotice list
34% of workforceRestructuring planSEC 8-K“(the “Company”) approved a reduction in force that is expected to result in the termination of approximately 34% of the Company’s workforce.”Filing
35% of workforceRestructuring planSEC 8-K“ITEM 2.05 Costs Associated with Exit or Disposal Activities On November 5, 2008, the Company, to better focus the its resources on APF530, announced implementation of a corporate r…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Heron Therapeutics, Inc. compares in Biotechnology

  • Market cap$57 M · higher than 28% of 726
  • Revenue$155 M · higher than 74% of 647
  • Net margin-14.6% · higher than 64% of 408
  • Revenue growth7.4% · higher than 51% of 438
  • Price / sales0.4× · lower than 98% of 339
  • Price / book4.0× · lower than 38% of 534
  • FCF yield-48.9% · higher than 24% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Heron Therapeutics, Inc.🇺🇸$57 M—-14.6%+7.4%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Heron Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Heron Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Heron Therapeutics, Inc.? Suggest a correction